- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04669951
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer
June 1, 2021 updated by: Michael Patrick Achiam
Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Adenocarcinomas
The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
- Sections of the tumor tissue will be HE stained.
- Sections of the tumor tissue will be stained with an uPAR antibody for immunohistochemistry.
- Immunohistochemical staining against cytokeratin which colors cancer cells will be made to assist the observer in the evaluation of uPAR microexpression pattern.
- A semiqualitative scale corresponding to the level of uPAR expression will be made.
- Quantitative polymerase chain reaction will be used to validate the immunohistochemistry uPAR expression pattern.
- An electronic scoring system (digital pathology) will be trained to access the expression of uPAR in both tumor- and normal tissue.
Study Type
Interventional
Enrollment (Actual)
100
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Region Hovedstaden
-
Copenhagen, Region Hovedstaden, Denmark, 2100
- Rigshospitalet
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years old.
- Patients who underwent curatively intended surgery for gastroesophageal cancer
- Patients who underwent surgery after 01-01-2016.
Exclusion Criteria:
- Patients who applied for an exception from medical research at the "National Registry of Tissue Use."
- Patients with other histological subtypes than adenocarcinoma.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: uPAR expression
Immunohistochemistry
|
Resected esophageal cancer will be qualitatively and semi-quantitatively analyzed for uPAR expression
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
uPAR microexpression
Time Frame: Up to 6 months
|
Our primary objective is to investigate uPAR microexpression in gastroesophageal adenocarcinomas both qualitatively and semi-quantitatively.
This will be done by a pathology analysis of gastroesophageal cancer resections.
|
Up to 6 months
|
Tumor-to-background ratio
Time Frame: Up to 6 months
|
A pathology staining will determine the uPAR in the tumor compared with the healthy cells.
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
uPAR in patient groups
Time Frame: Up to 6 months
|
Baseline statistical analysis of patient groups and their expression of uPAR in their resected tumor tissues will be made.
|
Up to 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Achiam, MD., Ph.D, Rigshospitalet, Department of Surgical Gastroenterology
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 18, 2019
Primary Completion (Actual)
November 30, 2020
Study Completion (Actual)
November 30, 2020
Study Registration Dates
First Submitted
December 2, 2020
First Submitted That Met QC Criteria
December 9, 2020
First Posted (Actual)
December 17, 2020
Study Record Updates
Last Update Posted (Actual)
June 3, 2021
Last Update Submitted That Met QC Criteria
June 1, 2021
Last Verified
June 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- uPAR ECV
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Esophagus Cancer, Adenocarcinoma
-
Activ SurgicalWest Penn Allegheny Health System; University of Pittsburgh Medical CenterRecruitingEsophageal Cancer | Esophageal Neoplasms | Esophageal Diseases | Esophageal Adenocarcinoma | Esophageal Squamous Cell Carcinoma | Esophagus Cancer | Esophagus Adenocarcinoma | Esophagus Tumor | Esophagus Neoplasm | Esophagus SCCUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaboratorsNot yet recruitingEsophageal Cancer | Barrett Adenocarcinoma | Barretts Esophagus With Dysplasia
-
Anwaar SaeedBristol-Myers Squibb; Clovis Oncology, Inc.RecruitingEsophagus Cancer, Adenocarcinoma | Stomach Cancer, AdenocarcinomaUnited States
-
St. James's Hospital, IrelandUnknownBarrett Esophagus | Siewert Type II Adenocarcinoma of Esophagogastric Junction | Oesophagus Cancer | Siewert Type I Adenocarcinoma of Esophagogastric Junction | Siewert Type III Adenocarcinoma of Esophagogastric JunctionIreland
-
Lucid Diagnostics, Inc.RecruitingBarrett Esophagus | Barretts Esophagus With Dysplasia | Esophagus AdenocarcinomaUnited States
-
Rigshospitalet, DenmarkNanoviCompletedEsophagus Cancer, AdenocarcinomaDenmark
-
CDx DiagnosticsIcahn School of Medicine at Mount Sinai; NYU Langone Health; University of Kansas... and other collaboratorsCompletedBarrett Esophagus | Esophagus Adenocarcinoma | Esophageal DysplasiaUnited States
-
University of Colorado, DenverRecruitingBarrett Esophagus | Esophageal Adenocarcinoma | Barretts Esophagus With DysplasiaUnited States
-
University of North Carolina, Chapel HillInterpace Diagnostics CorporationCompletedBarretts Esophagus With Dysplasia | Intramucosal AdenocarcinomaUnited States
-
Lucid Diagnostics, Inc.CompletedBarrett Esophagus | Esophageal Adenocarcinoma | Barrett's Esophagus Without Dysplasia | Barretts Esophagus With DysplasiaUnited States, Spain
Clinical Trials on uPAR immunohistochemistry
-
Rigshospitalet, DenmarkCompletedHead and Neck CancerDenmark
-
Groupe Francais De Pneumo-CancerologieCompletedLarge Cell Lung Cancer | Neuroendocrine Carcinoma of Lung (Diagnosis)France
-
Centre Hospitalier Universitaire, AmiensCompleted
-
Assiut UniversityNot yet recruiting
-
University Hospital, GrenobleInstitut National de la Santé Et de la Recherche Médicale, FranceNot yet recruitingFetal Growth Retardation | Pre-eclampsia | Pre-Term
-
Centre Hospitalier Departemental VendeeCompleted
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)Completed
-
Fondazione Policlinico Universitario Agostino Gemelli...Not yet recruiting
-
University of ArkansasCompletedNeurodegenerative Diseases | Alzheimer DiseaseUnited States